赫吉亚生物（Hangzhou Hejiya Biopharma） builds end-to-end siRNA drug development capabilities from target discovery to clinical proof-of-concept, centered on proprietary delivery platforms. Its platforms include MVIP (a dual-conjugate liver-targeting siRNA delivery platform with global patent authorization), a second-generation DDP liver delivery system for multiplexed siRNA delivery, and HJYNSdp for CNS/PNS targeting. The company’s pipeline spans HBV, NASH/MASH, ASCVD/metabolic disease, complement-mediated disorders and neurodegenerative indications, with multiple programs in clinical or IND‑enabling stages. One HBV siRNA asset licensed to Fosun’s StarYao Kunze has become the first domestic siRNA HBV drug authorized by both the NMPA and FDA to enter clinical trials. An ASCVD Lp(a) program has obtained NMPA clinical implicit approval, and a NASH program is in Phase I with favorable safety and tolerability signals reported. Following the financing, the company plans to accelerate clinical-stage programs and advance preclinical compounds toward IND filings to solidify its leading position in the siRNA field.

Total raised

$14M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2024